Story perspectives

New Breast Cancer Trial Shows Promising Treatment Advances

4/23/2025

50 12

Summary

Story summary

Joyce O’Shaughnessy, MD, unveiled groundbreaking advancements in breast cancer treatment, spotlighting the EMBER-3 trial that revealed imlunestrant's potential for HR-positive, HER2-negative patients. The trial demonstrated significant improvements in progression-free survival, particularly for those with ESR1 mutations. Promising ongoing studies on antibody-drug conjugates like ARX788 and datopotamab deruxtecan hint at a brighter future for therapy.

1 of 1

Story summary

Joyce O’Shaughnessy, MD, unveiled groundbreaking advancements in breast cancer treatment, spotlighting the EMBER-3 trial that revealed imlunestrant's potential for HR-positive, HER2-negative patients. The trial demonstrated significant improvements in progression-free survival, particularly for those with ESR1 mutations. Promising ongoing studies on antibody-drug conjugates like ARX788 and datopotamab deruxtecan hint at a brighter future for therapy.